Related Experiment Videos
Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report
B Greenberg1, A Berkman, R Thomas
1New York Academy of Medicine, Office of Special Population/Center for Urban Epidemiologic Studies, NY 10029, USA. bgreenberg@nyam.org
Journal of Urban Health : Bulletin of the New York Academy of Medicine
|December 28, 1999
Summary
In residential health care facilities, 50% of treatment-experienced patients with advanced HIV infection responded well to highly active antiretroviral therapy (HAART). This study highlights the importance of supervised, maximized adherence for successful HIV treatment outcomes.
Area of Science:
- Infectious Diseases
- Virology
- Public Health
Background:
- Advanced human immunodeficiency virus (HIV) infection presents challenges in treatment adherence and response.
- Residential health care facilities (RHCFs) offer a controlled environment to maximize medication access and adherence.
- Treatment-experienced patients often have complex medical histories and require tailored therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of highly active antiretroviral therapy (HAART) in treatment-experienced patients with advanced HIV.
- To assess HAART response in a setting that optimizes access and adherence, such as RHCFs.
- To identify factors influencing HAART response in a predominantly minority, injection drug user (IDU) population.
Main Methods:
- Retrospective medical record review of 111 patients in New York City HIV/AIDS designated RHCFs.
- Analysis of viral load changes and demographic data, including injection drug use (IDU) and hepatitis C virus (HCV) seropositivity.
- Comparison of HAART response between patients receiving supervised therapy and those not on HAART.
Main Results:
- 80% of patients were on HAART, with 52% achieving a decreased viral load (>1/2 log) compared to 13% not on HAART (P<.05).
- Viral load increase was observed in 8% of patients on HAART versus 35% not on HAART (P<.05).
- IDUs and HCV-seropositive patients were more likely to experience viral load increase, irrespective of initial CD4+ cell count or viral load.
Conclusions:
- Approximately 50% of treatment-experienced patients in this RHCF setting demonstrated successful response to supervised HAART.
- RHCFs provide a valuable model for studying factors affecting HAART response due to maximized adherence and monitoring.
- Further research in these controlled environments can elucidate specific factors contributing to successful HIV treatment outcomes in vulnerable populations.